Zacks Investment Research reissued their buy rating on shares of Primero Mining Corp (NYSE:PPP) in a research note released on Sunday, Market Beat reports. Zacks Investment Research currently has a $2.00 price objective on the stock.
Primero Mining Corp. (NYSE:PPP) belongs to Basic Materials sector. Its weekly performance is 5.88%. On last trading day company shares ended up at $1.62. Primero Mining Corp. (NYSE:PPP) distance from 50-day simple moving average (SMA50) is -24.44%.
Goldcorp Inc. (NYSE:GG) will release 2015 fourth quarter and full-year results after the market close on Thursday, February 25, 2016. The release will also include the Company’s guidance for 2016 and its mineral reserve and mineral resource statement as of December 31, 2015.
Goldcorp Inc. (NYSE:GG) shares increased 2.05% in last trading session and ended the day at $15.43. GG Gross Margin is 8.10% and its return on assets is -8.20%. Goldcorp Inc. (NYSE:GG) quarterly performance is 27.51%.
NVIDIA Corporation (NASDAQ:NVDA) is pushing the newfangled Vulkan graphics API to the SHIELD console, for better graphics resource management. Android Marshmallow to the NVIDIA SHIELD console means we get all the power efficiency, tweaks, new features, and performance gains that Google pushed to the latest version of Android.
On 23 February, NVIDIA Corporation (NASDAQ:NVDA) shares moved up 0.25% and was closed at $31.60. NVDA EPS growth in last 5 year was 20.20%. NVIDIA Corporation (NASDAQ:NVDA) year to date (YTD) performance is -4.13%.
On 18 February, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announces Duncan Pilgrim, vice president and general manager of the high performance analog business unit, will speak at the Compound Semiconductor (CS) International Conference on Tuesday, March 1 in Brussels, Belgium.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $1.05. Company weekly volatility is calculated as 8.71% and price to cash ratio as 3.35. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of 14.13%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced that the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data included in ACADIA’s New Drug Application (NDA) for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. The Advisory Committee Meeting is scheduled for March 29, 2016.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares moved down -4.62% in last trading session and ended the day at $19.19. ACAD return on assets is -51.20%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly performance is -46.50%.